UniQuest Pty Ltd

UniQuest is the commercialisation company of The University of Queensland (UQ).  In partnership with UQ researchers, we create impact through the commercialisation of UQ intellectual property (IP). Established in 1984, UniQuest’s commercialisation track record positions UQ as the leader of research commercialisation in Australasia.  UniQuest has formed more than 130 start-up companies built on UQ IP. These companies have gone on to raise more than A$1 billion to take UQ technologies towards the market and have directly created more than 450 new jobs. Our track record and notable successes include the blockbuster cervical cancer vaccine GARDASIL® and start-up companies Spinifex Pharmaceuticals Inc and Inflazome Ltd, which were acquired in two of the largest university start-up exits in Australian history. UniQuest has managed more than 360 US granted patents based on UQ IP. Marketed products containing UQ IP licensed by UniQuest have generated gross sales of more than A$88 billion and have significantly contributed to societal and economic impact. According to the 2023 Survey of Commercialisation Outcomes from Public Research (SCOPR), UQ leads the Group of Eight universities in commercialisation revenue received, the number of active start-ups and the value of equity held in start-ups formed from university IP.  UniQuest has also established the Queensland Emory Drug Discovery Initiative (QEDDI) - a world-class small molecule drug discovery and development group –dedicated to translating biomedical research into drug candidates for partnering. QEDDI’s projects target some of the world’s most challenging health problems, including cancer, inflammatory diseases and neurodegenerative disorders.